News articles about K2M Group (NASDAQ:KTWO) have trended positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. K2M Group earned a news sentiment score of 0.41 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 47.0664409923005 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
KTWO has been the topic of a number of recent analyst reports. Needham & Company LLC lowered their price target on shares of K2M Group from $27.00 to $26.00 and set a “strong-buy” rating on the stock in a research note on Thursday, November 2nd. Wells Fargo & Co lowered shares of K2M Group from an “outperform” rating to a “market perform” rating and set a $23.00 price objective on the stock. in a research report on Monday, December 4th. Oppenheimer reiterated a “buy” rating and issued a $24.00 price objective on shares of K2M Group in a research report on Friday, November 10th. Zacks Investment Research lowered shares of K2M Group from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Barclays restated a “buy” rating and issued a $25.00 target price on shares of K2M Group in a report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.50.
Shares of K2M Group (NASDAQ KTWO) traded up $0.13 during trading hours on Friday, reaching $19.33. 139,558 shares of the company’s stock traded hands, compared to its average volume of 294,498. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67. K2M Group has a one year low of $16.44 and a one year high of $25.99. The firm has a market capitalization of $837.54, a P/E ratio of -20.14 and a beta of 1.47.
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.